Midazolam has been used in combination with other drugs as an anti emetic for persistent postoperative nausea and vomiting! and in patients receiving chemotherapy'. This report describes the successful use of low-dose midazolam infusion in combination with total parenteral nutrition (TPN) and antidopaminergics in the management of life-threatening hyperemesis gravidarum.
CASE REPORT
A 33-year-old, 74-kg teacher, G3 PI, with type I insulin-dependent diabetes presented at 17 weeks gestation with hyperemesis gravidarum and mild diabetic ketoacidosis. Blood glucose was 19.4 mmolll and she had a metabolic acidosis with significant ketonuria. There was no other cause for her symptoms. Human chorionic gonadotrophin was appropriate for her gestational age, and the fetus was normal at ultrasound.
She was rehydrated with normal saline (6 litres over 24 hours) and commenced on a sliding scale of insulin which was titrated against two-hourly blood sugar estimation. A variety of antiemetics including meclizine, pyridoxine, prochlorperazine, metoclopramide and droperidol were tried over several days in standard doses without success. After ten days, despite normalization of her biochemistry and psychological support, symptoms had worsened with constant retching and occasional coffee-ground vomiting. She was unable to tolerate any food and did not wish to see a psychiatrist. Upper gastrointestinal endoscopy revealed an inflamed lower oesophagus and gastroparesis but no Mallory Weiss tear, and she was given ranitidine.
In view of the severity of symptoms and concerns about lower oesophageal integrity, she was given midazolam 2 mg intravenously followed by an infusion of 1 mg/hr. In addition, a subclavian central line was inserted and parenteral nutrition was commenced. Enteral feeding was not attempted because of concerns that a nasogastric tube might worsen the oesophagitis. She continued to receive prochlorperazine 12.5 mg IM, 6-8 hourly. There was no improvement in nausea (as judged by visual analog score 0-10) over the first ten hours and the midazolam infusion was increased to 1.5 mg/hr. Symptoms gradually subsided over the next 3 to 6 hours. The patient was not excessively sedated and there was no episode of respiratory depression. On three occasions during the next two days, it was noted that symptoms worsened when the midazolam infusion was turned off. Whilst the infusion was running, however, symptoms were tolerable and within four days she had improved sufficiently to commence a light diet. Prochlorperazine was ceased on day 3 when the patient developed mild extrapyramidal symptoms. Parenteral nutrition was ceased on day 6 and the midazolam on day 7. By day 8 the patient was on a full diet with only slight nausea. The patient discharged herself on day 10 and initially was reasonably well. At 28 weeks' gestation, however, she was readmitted with severe recurrent symptoms and on this occasion insisted on delivery of the baby. Total parenteral nutrition was again commenced and conventional antiemetic pharmacotherapy reinstigated (vide supra). In the author's absence, midazolam was not used although ondansetron was tried without success. After ten days she became febrile and developed peripheral oedema. The central line was removed, she was given dexamethasone and underwent a caesarean section giving birth to a normal 1.5 kg female. Postnatally the nausea and vomiting subsided and she was able to tolerate food, but she developed post-natal depression and agreed to see a psychiatrist.
DISCUSSION
Hyperemesis gravidarum is a poorly understood disorder which occurs in approximately 2070 of pregnancies and is characterized by persistent vomiting Anaesthesia and Intensive Care, Vul. 23, Nu. 2, April, 1995 leading to dehydration, electrolyte disturbance and ketosis 3 • 4 • Psychological factors are involved in its pathogenesis, with some patients fulfilling the criteria for a conversion reactions. Hormonal and physical factors may also contribute. One third of patients with hyperemesis gravidarum develop transient hyperthyroxinaemia and this may be associated with high levels of oestrogen 6 • 7 • It has also been suggested that reflux oesophagitis in combination with gastric dysrhythmia may be the cause 8 • 9 • Although commonly occurring in the first trimester it can persist into the second or third trimester'o. Symptoms often disappear abruptly". There is evidence that severe hyperemesis is associated with a greater risk of growth retardation and fetal abnormalities 12 • Treatment includes fluid and electrolyte supplements and nutritional support as well as psychological and behavioural therapies 3. In selected cases pharmacotherapy and enteraI 4 • 13 or total parenteral nutrition lO • 14 is required. Until recently experience with TPN during pregnancy was limited, but it appears to be a safe and effective method for reversing maternal malnutrition and promoting fetal growth I4 • 15 • It has been used for up to 132 days without complications lO • 14 • Ideally, antiemetics should be avoided wherever possible because of the susceptibility of the fetus to chemical insult and developmental defects. However, it is generally considered safer to give a drug that will effectively control vomiting rather than to subject the fetus to the adverse effects of maternal dehydration, ketosis and malnutrition. Commonly used drugs are meclizine, pyridoxine, metoclopramide, prochlorperazine and droperidol, all of which present a relatively low risk to the fetus, particularly during the second trimester'6. Ondansetron has also been successfully used in one patient 17 , but was ineffective in this instance. Although there is evidence of fetal risk with benzodiazepines, their use is justified in life-threatening situations where safer drugs are ineffective'6. Lorazepam has been successfully used in the management of hyperemesis gravidarum and with no adverse fetal effects 18. There is no data available about the effects of midazolam on the fetus.
In this patient the problem was complicated by mild diabetic ketoacidosis. Pregnant diabetics with hyperemesis frequently develop ketoacidosis and 30<170 of these patients have a pre-pregnancy history of autonomic gastropathy'9. It is not known if autonomic gastropathy predisposes to the development of hyperemesis. Gastroparesis was present in this patient at endoscopy and may have been related to pregnancy or diabetes.
In this case, the combination of midazolam, prochlorperazine and TPN resulted in an improvement in symptoms which were sustained for some weeks after therapy ceased. In retrospect it would have been ideal to have introduced the TPN and midazolam separately, but the severity of the condition dictated a more aggressive approach. It had already been established that prochlorperazine alone was ineffective. The timing of events suggests that midazolam played a role in management, although TPN itself may result in the prompt improvement in symptoms 20 • Di Florio has postulated that benzodiazepines not only reduce the psychic input to the vomiting centre but also interfere with dopamine synthesis, release and action in the chemoreceptor trigger zone'. Benzodiazepines would therefore be expected to be synergistic with, or additive to antidopaminergic drugs in the control of nausea and vomiting, and for this reason prochlorperazine was continued. It is possible that this same interaction led to the early onset of extrapyramidal symptoms.
